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Abstract 1 
Degenerative myelopathy is a late-onset, slowly progressive degeneration of spinal cord white 2 
matter which is reported primarily in large breed dogs. The missense mutation  SOD1:c.118G>A is 3 
associated with this pathology in several dog breeds, including the German Shepherd Dog. The 4 
aims of the present study were to develop a tool for the rapid screening of the SOD1 mutation site in 5 
dogs and to evaluate the association of the polymorphism with degenerative myelopathy in the 6 
German Shepherd breed. Two different techniques were compared: a minisequencing test and a 7 
Real-Time PCR Allelic Discrimination assay. Both approaches resulted effective and efficient. A 8 
sample of 47 dogs were examined. Ten subjects presented the symptoms of the illness; for one of 9 
them the diagnosis was confirmed by postmortem investigations and it resulted to be an A/A 10 
homozygote. In another clinically suspected dog, heterozygote A/G, the histopathological 11 
examination of the medulla showed moderate axon and myelin degenerative changes. German 12 
Shepherd Dog shows a frequency of the mutant allele equal to 0.17, quite high being a high-risk 13 
allele. Because canine degenerative myelopathy has a late onset in adulthood and homozygous 14 
mutant dogs are likely as fertile as other genotypes, the natural selection is mild and the mutant 15 
allele may reach high frequencies. A diagnostic test, easy to implement, may contribute to control 16 
the gene diffusion in populations. The SOD1:c.118G>A mutation could be a useful marker for 17 
breeding strategies intending to reduce the incidence of degenerative myelopathy. 18 
 19 
 20 
Keywords: German Shepherd Dog, SOD1, Primer-Extension Reaction, Real Time PCR, Allelic 21 
discrimination.22 
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Introduction 1 
Degenerative myelopathy (DM) is a late-onset, slowly progressive degeneration of the spinal cord 2 
white matter which is reported primarily in large-breed dogs. The condition has been described in 3 
German Shepherd Dog (GSD) as well as in other breeds like Siberian Husky, Miniature Pooddle, 4 
Boxer, Pembroke Welsh Corgi, Chesapeake Bay Retriever, and Rhodesian Ridgeback 1. Dogs 5 
with DM show an insidiously progressive ataxia and paresis of the pelvic limbs, ultimately leading 6 
to loss of the ability to ambulate within 6 to 12 months of the onset of signs. Definitive diagnosis of 7 
DM is confirmed by postmortem histological examination of the spinal cord 2. There is no sex 8 
bias. Most dogs are at least 8 years old before the onset of clinical signs 1. DM appears to be an 9 
autosomal, recessive, and incompletely penetrant  disease 3. 10 
Human amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by 11 
adult-onset, progressive loss of motor neurons in the motor cortex, brainstem and spinal cord (lower 12 
motor neurons), leading to muscle atrophy, generalized paralysis, respiratory depression, and 13 
inevitable death 4, 5, 6, 7. In 1993, mutations in superoxide dismutase 1 (SOD1) gene were 14 
associated with familial ALS 8. So far, more than a hundred SOD1 different mutations have been 15 
identified in ALS patients. Mutations in other genes have been reported to account for a small 16 
number of cases of familial ALS 9. 17 
Interestingly, relationship between the missense mutation  SOD1:c.118G>A  and canine DM has 18 
recently been reported 3.This mutation was associated with DM in several dog breeds, including 19 
the GSD. The related SNP could be a useful marker for breeding strategies intending to reduce the 20 
incidence of DM.  21 
The first aim of the present study was to develop a tool for rapid screening of the SOD1 mutation 22 
site in dogs comparing two different molecular approaches: i) minisequencing (or Primer-Extension 23 
Reaction - PER) and ii) Real-Time PCR Allelic Discrimination TaqMan MinorGroove Binding 24 
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(MGB). The second aim was to evaluate the association of SOD1c.118G>A mutation with DM in 1 
GSD.  2 
 3 
Materials and methods 4 
Sample collection  5 
Peripheral blood samples were collected from 47 GSD of both genders aged from 5 months to 14 6 
years, including 10 clinically suspected of having a progressive neurological disease. Dogs were 7 
patients from the Veterinary Hospital, University of Turin, and from several private veterinary 8 
practitioners. Blood samples were stored at -22°C until analysed.  9 
DNA extraction 10 
Genomic DNA was obtained from blood using the NucleoSpin Blood Quick Pure kit (Macherey-11 
Nagel GmbH & Co. KG, Düren, Germany) , according to the manufacturer protocol, and stored at -12 
20°C until use. DNA purity was evaluated by absorbance readings using the NanoDrop-2000 13 
(Thermo Fisher Scientific Inc., Waltham, Massachusetts).  14 
Minisequencing test 15 
The PER reaction is based on the addition of a [F]ddNTP to the 3’ end of an unlabeled 16 
oligonucleotide (sequencing primer) in the absence of dNTPs in the reaction. Each  [F]ddNTP is 17 
labeled with a specific fluorescent dye and each sequencing primer is designed immediately 18 
adjacent to the diagnosis site. 19 
Preliminary PCR 20 
The PCR primers used in the preliminary PCR tests are shown in Fig.1 (Eurofins MWG Operon, 21 
Ebersberg, Germany)
 3, PCR reactions were performed in 50 μL volumes consisting of 0.04 U/μL 22 
HotStarTaq (Qiagen, Hilden, Germany), 0.2 mM each of dNTPs,0.5 μM of each primer, and 50-100 23 
ng of DNA template. The PCR profile consisted of an initial activation step at 95°C for 15 min, 24 
followed by 35 cycles of 95°C denaturation for 30 sec, annealing at 60°C for 30 sec, and extension 25 
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at 72°C for 30 sec. A final extension step of 72°C for 7 min was added to all reactions. 1 
Amplifications were carried out using a GeneAmp PCR System 2720 thermal cycler (Applied 2 
Biosystems by Life Technologies Italia, Monza, Italy). Amplicons were resolved on a 2.5% agarose 3 
gel. 4 
Primer-Extension Reaction  (PER) 5 
The PCR products acted as templates for PER after enzymatic clean up. In order to remove primers 6 
and unincorporated dNTPs, 2 μL of Exo-Sap (GE Healthcar Europe Gmbh, Glattbrugg, Schweiz) 7 
were added to 5 μL of PCR products. Tubes were incubated at 37°C for 1 h and at 80°C for 15 min.   8 
Based on SOD1 sequence alignments, the sequencing primer was designed upstream from the 9 
SOD1 mutation site associated with DM (5’- GAACCATTACAGGGCTGACT -3’) (Fig. 1) PER 10 
reactions were performed following the SNaPshot multiplex Kit protocol (Applied Biosystems by 11 
Life Technologies Italia, Monza, Italy) with minor modifications: 2.5 μL of Ready Reaction Mix, 12 
3μL of purified amplicons from the preliminary PCR, diluted to obtain a range of 0.4-0.01 pmol and 13 
0,2μM of sequencing primer in a total volume of 10μL. The reactions underwent 25 single base 14 
extension cycles of denaturation at 96°C for 10 s, annealing at 50°C for 5 s, and extension at 60°C 15 
during 30 s. The reactions were carried out in a GeneAmp PCR System 2720 thermal cycler 16 
(Applied Biosystems by Life Technologies Italia, Monza, Italy). 17 
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Subsequently, a post-extension treatment to remove 5’-phosphoryl group of the [F]ddNTPs helped 1 
to prevent unincorporated [F]ddNTPs co-migrating with the extended primers and producing a high 2 
background signal. For this purpose, the final volume (10 μL) was treated with 1 unit of Calf 3 
Intestine Alkaline Phosphatase (Invitrogen by Life Technologies Italia, Monza, Italy). The tubes 4 
were incubated at 37°C for 1 hr and at 65°C for 15 min. Finally, samples were prepared by adding 1 5 
μL of the post-PER product to 12 μL of formamide and 0.2 μL of GeneScan 120 LIZ size standard. 6 
Each sample was loaded on the ABI 310 Genetic Analyzer and analyzed using Pop4 polymer, a 47-7 
cm capillary column, the ABI GeneScan E5 Run Module. Parameters for this analysis are the 8 
following: injection time 12 s and run time 15 min. Electropherograms were analysed using the 9 
GeneScan 3.1.2 software (Applied Biosystems by Life Technologies Italia, Monza, Italy) 10 
Real-Time PCR Allelic Discrimination test 11 
In our study, we develop a Real-Time PCR Allelic Discrimination TaqMan MGB assay based on 12 
the SOD1:c.118G>A mutation analysis.  13 
Recently, the Real-Time PCR Allelic Discrimination test has been largely used to genoptype 14 
individual DNA at known muatation site 10. 15 
During amplification, the fluorogenic TaqMan probes anneal specifically to complementary 16 
sequences between forward and reverse primer binding sites on the DNA template and they are then 17 
degraded owing to the 5’-3’ exonuclease activity of DNA polymerase. Once separated from the 18 
quencher, the reporter dye emits fluorescence, which is read by the Real-Team PCR system. 19 
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In the assay here described, the two probes are 100% identical with their respective target 1 
sequences; only a single mismatch in the 5’ end is observed between them. The contemporary 2 
presence of the two probes allows the annealing of both regardless of the allele present because the 3 
single mismatch does not impair the probes’ annealing to heterologous DNA. During the extension, 4 
the 5’-3’ Exonuclease activity of the DNA polymerase degrades the probe that is totally identical to 5 
the template with a consequent fluorescent emission. On the contrary, the probe that has a mismatch 6 
with the sequence is removed without degradation and devoid of fluorescent emission. The post-7 
PCR analysis allows the instantaneous visualization of the results by mean of a specific plot.      8 
Primer and probe design 9 
The PCR primers 3 were used in conjunction with two MGB probes (Applied Biosystems by Life 10 
Technologies Italia, Monza, Italy). One probe was designed to specifically hybridize, with a 100% 11 
of identity, to one allele (SOD1_ProbeA 5’- 6FAM-CTGACTAAAGGCGAG -3’) and the other one 12 
to the second allele (SOD1_ProbeG 5’- VIC-CTGACTGAAGGCGAGC -3’) (Fig. 2). 13 
Analysis of diagnostic site 14 
Real-time PCR was performed in a 25 μL reaction mixture containing 900 nM of both forward and 15 
reverse primers, 200 nM of each probe, 12.5 μL of TaqMan Universal Master Mix (Applied 16 
Biosystems by Life Technologies Italia, Monza, Italy), and 30-50 ng of DNA template. Thermal 17 
cyclings were performed on a 7300 Real-Time PCR system (Applied Biosystems by Life 18 
Technologies Italia, Monza, Italy)  under the following conditions: 95°C for 10 min, and 45 cycles 19 
of 95°C for 15 s and 60°C for 1 min. All PCR reactions were run in duplicate.  20 
Results were obtained by the automatic calling feature of the Allelic Discrimination option in SDS 21 
v1.2.1 software. Alleles were assigned to samples by visual inspection of a plot of the fluorescence 22 
(Rn) from the A probe versus Rn from G probe generated from the post-PCR fluorescence read. 23 
 24 
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Sequencing 1 
DNA sequencing was carried out as a confirmatory test. Amplified fragments of the preliminary 2 
PCR of a homozygous AA dog and a homozygous GG animal were cloned into the pDRIVE 3 
Cloning Vector using QIAGEN PCR Cloning Kit (GE Healthcar Europe Gmbh, Glattbrugg, 4 
Schweiz). Clones were subsequently submitted to RFLP analysis using Hae III to choose a clone 5 
that contained the diagnostic site. These cloned fragments were cycle sequenced on an ABI PRISM 6 
310 Genetic Analyser (Applied Biosystems by Life Technologies Italia, Monza, Italy) , using the 7 
ABI Prism BigDye terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems by Life 8 
Technologies Italia, Monza, Italy), version 1.1 by the dideoxy chain termination method with 9 
fluorescence dye terminators. The sequencing on both strands was performed using the two M13 10 
vector primers. The resulting sequences were compared and aligned with ‘ClustalW’ program11. 11 
 12 
Results 13 
Minisequencing test 14 
The primers used for the preliminary PCR successfully amplified a 79 bp fragment. For 15 
homozygote dogs the PER analysis gave rise to a peak of the color that is specific to the nucleotide 16 
present on template, green for A and blue for G. In heterozygote animals both peaks, green and 17 
blue, were generated (Fig. 3). On 47 GSDs analysed by minisequencing, two homozygote 18 
individuals for the mutant allele (AA) were detected, 12 heterozygous GA, all other dogs were 19 
homozygote  for the wild allele (GG).    20 
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Real-Time PCR Allelic Discrimination test 1 
Real-Time PCR Allelic Discrimination test confirmed the genotypes obtained with PER. A 2 
representative plot used to genotype individuals is displayed in Fig 4. The Real Time test was 3 
applied to all 47 individuals. Two dogs were confirmed to be A/A, 33 dogs were G/G and 12 G/A. 4 
In the examined cohort the allele frequencies were 0.17 and 0.83 for A and G, respectively. 5 
Sequencing 6 
Ultimately, the sequencing of the amplicons obtained from the preliminary PCR confirmed the 7 
reliability of both techniques for genotyping the SOD1:c118G>A polymorphism in dog. 8 
Association between DM and SOD1c.118G>A  9 
Out of the 47 dogs examined in this study, 10 were clinically suspected to have DM. Therefore, 10 
depending on availability of tissues and clinical information, diagnoses of DM were made on the 11 
basis of criteria of varying stringency. Only in one case the clinical diagnosis was confirmed by 12 
postmortem investigations (histopathology of the spinal cord tissue) (data not shown). It was a 13 
male, 8 years old, and it resulted to be an A/A homozygote. In another clinically suspected dog, a 14 
male 14 years old, heterozygote A/G, the histopathological examination of the medulla showed only 15 
moderate axon and myelin degenerative changes limited to the thoracic segments. One more A/A 16 
clinically suspected animal is still alive. For all the other clinically suspected dogs (1 A/G and 6 17 
G/G) the diagnosis was not confirmed by histopathological examination of the medulla or 18 
unfortunately the necropsy was not carried out.  19 
From the other 37 dogs not suspected to have DM, none was homozygote A/A, 27 were 20 
homozygotes G/G, and the other heterozygotes. 21 
 22 
Discussion 23 
In a previous study SOD1 in normal and DM affected dogs was sequenced and a G to A transition 24 
in exon 2, predicting an E40K missense mutation, was observed 3. Homozygosity for the A allele 25 
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was highly associated with DM in five dog breeds (GSD, Pembroke Welsh Corgi, Boxer, 1 
Rhodesian ridgeback, and Chesapeake Bay retriever); therefore the A allele was recognized as a 2 
major genetic risk factor for the disease. Recently, two genotyping assays for the SOD1 mutation, 3 
using conventional and Real Time PCR methods have been proposed 12. The aim of our study 4 
was to develop a test for rapid screening and identification of SOD1:c118G>A mutation carriers in 5 
dogs using two different approaches: a minisequencing test and a Real-Time PCR Allelic 6 
Discrimination test. Both approaches are effective and efficient, all genotypes were clearly 7 
determined without non-specific allelic amplification. Costs for consumables and reliability of 8 
results are similar. Real Time Allelic Discrimination test provides several advantages because it 9 
does not require any post-amplification step and utilizes 96-well format plates that can be read in 10 
about 5 min, enabling a rapid diagnosis of large numbers of samples. On the other hand, the reads 11 
of the minisequencing test have a precision comparable to that of the sequencing. This technique 12 
can be suitable for automation and high-throughput testing for laboratories equipped with an ABI 13 
sequencer. In comparison with sequencing, the minisequencing has the advantage of being quicker, 14 
allowing an immediate interpretation of the results. Moreover, it may be implemented for the 15 
multiplex analysis of several mutation sites. Recently, a novel SOD1 missense mutation, associated 16 
with DM, has been described in the Bernese Mountain Dog breed 13. It would be interesting to 17 
implement a minisequencing test for the concurrent genotyping of multiple SNPs. Ultimately, the 18 
choice of the more suitable approach depends on laboratory disposable equipment.  19 
Representatives of 217 different dog breeds were genotyped at SOD1:c.118G>A and 115 of them 20 
were found to segregate the A allele 14.The Wire Fox Terrier had the highest SOD1:c.118A allele 21 
frequency (0.98). Likewise, in a survey on Pembroke Welsh Corgi, the mutant allele was found to 22 
be prevalent (0.68) 12. In the present investigation, GSD shows a frequency of the mutant allele 23 
equal to 0.17, quite high being a high-risk allele. Because canine DM has a late onset in adulthood 24 
and homozygous mutant dogs are likely as fertile as other genotypes, the natural selection is mild 25 
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and the mutant allele may reach high frequencies. A diagnostic test, easy to implement, may 1 
contribute to control the gene diffusion in populations. 2 
According to the hypothesis of Awano 3, the DM seems to be an age-related, incompletely 3 
penetrant disease. As far as the gene action is concerned, a model of inheritance based on dominant 4 
allele, as in humans, may not be excluded. In fact, not only the homozygote dogs exhibit clinical 5 
signs, but also heterozygote animals develop the pathology, although very slowly. Therefore, the 6 
clinical signs become apparent solely in dogs surviving longer the usual canine life span.  7 
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Legends for figures 1 
Fig. 1 Primers design for minisequencing (preliminary PCR primers in bold and PER primer in 2 
grey). The bases in the box correspond to the SOD1 mutation site.  3 
Fig. 2 Primers and probes design for Real-Time PCR Allelic Discrimination (primers in bold and  4 
probes in grey). The bases in the box correspond to the SOD1 mutation site. 5 
Fig. 3 Minisequencing patterns for the three genotypes: G/G (a), A/A (b), and G/A (c).    6 
Fig. 4 Real-Time PCR Allelic Discrimination plot. Fluorescence of G (x-axis) and A (y-axis) 7 
probes: no-template controls (squares), G/G (circles), A/A (diamonds), and G/A (triangles).   8 
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